1-Oxidoazepan-1-ium-4-thiol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 1-Oxidoazepan-1-ium-4-thiol
• 英文别名: 1-oxidoazepan-1-ium-4-thiol
• 化学式: C6H13NOS
• 分子量: 147.24
• InChiKey: NFWSQIAMFWJVHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  22.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS
  申请人：Fluorinov Pharma Inc.

  公开号：EP2885314A1

  公开（公告）日：2015-06-24
• [EN] FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS<br/>[FR] COMPOSÉS À BASE D'ÉPOXYCÉTONE FLUORÉS ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DU PROTÉASOME
  申请人：SLASSI ABDELMALIK

  公开号：WO2014026282A1

  公开（公告）日：2014-02-20

  The present application relates to novel fiuorinated epoxyketone-based compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition, in particular, the present application includes compounds of Formula I, and compositions and uses thereof:
• [EN] FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS<br/>[FR] COMPOSÉS TÉTRAPEPTIDIQUES À BASE D'ÉPOXYCÉTONE FLUORÉE ET LEURS UTILISATIONS EN TANT QU'INHIBITEUR DU PROTÉASOME
  申请人：SLASSI ABDELMALIK

  公开号：WO2014029022A1

  公开（公告）日：2014-02-27

  The present application relates to novel fluorinated epoxyketone-based tetrapeptide compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition. In particular, the present application includes compounds of Formula I, and compositions and uses thereof:
• [EN] METHODS OF TREATING BREAST CANCER<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER DU SEIN
  申请人：YEDA RES & DEV

  公开号：WO2021048852A1

  公开（公告）日：2021-03-18

  A combination of agents for use in the treatment of triple negative breast cancer (TNBC) is disclosed. The combination of agents comprise: (i) a Bromodomain and Extra-Terminal motif (BET) inhibitor; and (ϋ) a proteasome inhibitor or an agent which downregulates the amount and/or activity of CXCRl/2 receptor.